Humacyte submits supplemental biologics license application to FDA for dialysis access vessel
HUMA•Humacyte submitted a supplemental biologics license application to the FDA for its acellular tissue engineered vessel in dialysis access and requested priority review.
1. FDA application
Humacyte submitted the application for its acellular tissue engineered vessel in dialysis access and requested priority review.




